Close

Intra-Cellular (ITCI) Presents New Data From the Ph-2 Trial of ITI-007 at APA

May 6, 2014 2:31 PM EDT Send to a Friend
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login